Botox, Fillers, and the FDA: What Gets a Med Spa a Warning Letter

What actually gets a medical spa an FDA Warning Letter? In the aesthetics world it is rarely a stretched adjective on a service page. It is four concrete things: selling or marketing unapproved or imported (“foreign,” “generic”) injectable botulinum toxin, often without requiring a prescription; dispensing and handling violations, like injecting more units than you purchased or sourcing outside the legitimate supply chain; marketing unapproved compounded or over-the-counter topical numbing creams for cosmetic use; and absolute outcome claims (“permanent,” “risk-free,” “no downtime”) for neurotoxins and fillers. This post walks through each trigger using real, public cases, and shows the safer way to say what you actually mean.

TL;DR

• Unapproved or “foreign” toxin is the number-one trigger. Selling or advertising imported botulinum toxin that is not FDA-approved, especially without requiring a prescription, is treated as distributing an unapproved and misbranded drug. Beauty of Aztlan LLC drew an FDA Warning Letter in April 2026 for exactly this [3].
• Your unit math has to balance. A med spa that dispenses or injects more toxin units than it actually purchased is a dispensing and supply-chain red flag. Pure Indulgence Aesthetics was cited in April 2026 after an inspection found unit counts that did not add up [3].
• Topical numbing creams count as drugs. Compounded or OTC anesthetic creams marketed for use before cosmetic procedures are unapproved drugs when promoted with treatment-style claims. TKTX USA was cited in February 2025 over five such products [3].
• “Permanent,” “risk-free,” and “no downtime” are claims you cannot keep. Absolute safety and outcome language for Botox and fillers is unsubstantiated and deceptive under FTC standards [1][4].
• A scan is not a clearance. Our free tools and this post are educational screening. Your clinic’s own licensed physician and your counsel remain the final gate on any medical claim or product you market.

If you run a med spa, none of these traps require bad intent. A supplier’s listing gets pasted onto your site, a booking page promises “zero downtime” because that is what clients want to hear, and a numbing cream you have used for years shows up in your pre-care copy. Each one is a documented enforcement pattern. Here is what trips each, drawn from real cases, and how to phrase it safely. For the broader picture across all clinic types, see the pillar guide on the marketing claims that trigger FDA Warning Letters.

Pattern 1: Selling or marketing unapproved injectable toxin

This is the single biggest source of aesthetics enforcement, and it has two parts that often appear together: the product itself is not FDA-approved, and it is being sold without requiring a prescription.

In April 2026, the FDA issued a Warning Letter to Beauty of Aztlan LLC for selling unapproved and misbranded injectable botulinum toxin products, including listings for “Botulax 100units” and “Innotox 50units,” directly through a website without requiring a prescription [3]. You can read the full entry in our Beauty of Aztlan Atlas record. The core problem is definitional. Under the Food, Drug, and Cosmetic Act, an injectable botulinum toxin is a prescription drug, and the only botulinum toxin products the FDA has approved are a specific, named set. Anything outside that set, including imported products marketed as “foreign,” “generic,” or cheaper alternatives, is an unapproved new drug the moment it is offered for sale [2]. Selling it over a public web listing, with no prescription gate, also makes it misbranded.

What trips it: words like “generic Botox,” “imported,” “foreign toxin,” brand names that are not FDA-approved in the United States, price-shopping language (“same results for less”), and any e-commerce flow that lets someone buy injectable toxin without a prescription.

Safer phrasing and practice: name only FDA-approved neurotoxin products you actually administer, describe them as prescription treatments performed by a licensed provider after consultation, and never list injectable toxin for direct online purchase. “Our injectors administer FDA-approved neurotoxin during an in-person visit” is a true, defensible statement. “Buy generic Botox online” is an enforcement headline waiting to happen.

Pattern 2: Dispensing and supply-chain violations

Even when the product is legitimate, how you handle and account for it matters. The FDA and state boards expect the units you inject to trace back to units you lawfully purchased through the legitimate supply chain.

In April 2026, the FDA cited Pure Indulgence Aesthetics, a med spa in Southlake, Texas, after an inspection found it had dispensed significantly more Botox units to patients than it had purchased [3]. When the math does not reconcile, it signals one of two things to a regulator: either product is being sourced outside the legitimate supply chain, or it is being over-diluted or stretched in ways that raise safety and misbranding questions. Both are dispensing violations.

What trips it: purchase records that do not support your injection volume, product acquired from gray-market or overseas resellers, and dilution practices that quietly increase the number of “units” delivered per vial.

Safer practice, and safer copy: buy only through authorized distributors, keep purchase-to-administration records that reconcile, and avoid marketing that implies bargain pricing your legitimate supply costs cannot explain. This one is less about a single phrase and more about not advertising a price or volume that your real supply chain cannot back. If your marketing promises unusually cheap injectables, expect that claim to invite a look at your sourcing.

Pattern 3: Topical anesthetics and outcome claims

Two more patterns round out the aesthetics enforcement picture: unapproved numbing creams, and the absolute outcome claims that show up on nearly every med spa booking page.

On the topical anesthetic side, compounded or over-the-counter numbing creams marketed for use before cosmetic procedures are drugs in the FDA’s eyes when they carry treatment-style claims, and many are unapproved or misbranded. In February 2025, TKTX USA was cited over five topical numbing cream products marketed for pre-procedure cosmetic use [3]. A cream is not automatically a problem; marketing an unapproved or high-strength compounded anesthetic with claims about numbing for injections or laser is. Safer approach: use and reference only properly labeled, appropriately sourced anesthetics, and let your licensed provider determine and document what is applied, rather than promoting a specific unapproved product by name on your site.

On the outcome-claims side, the words “permanent,” “risk-free,” “no downtime,” and “guaranteed” applied to neurotoxins and fillers are claims you cannot substantiate. Neurotoxin results are temporary by design, every injectable carries some risk, and recovery varies by person. Absolute claims like these are exactly the deceptive, unsubstantiated language the FTC polices under Section 5, where the standard is competent and reliable scientific evidence [1][4]. Safer phrasing: “results typically last three to four months,” “most clients return to normal activities the same day,” and “common side effects include temporary bruising or swelling.” You keep the appeal and lose the liability.

How to check your med spa copy

You do not have to memorize this list. Paste your service pages, booking copy, and injectable descriptions into our free Claim Checker and it scans the text against the same FDA Warning Letter and FTC patterns these cases came from, including unapproved-product language, absolute-safety wording, and outcome guarantees. Every flag shows the regulator precedent next to it, so you can see why a phrase is risky and what to say instead. Nothing leaves your browser.

For the underlying cases themselves, browse the medical-spa category in the FDA / FTC Atlas, where each enforcement action is summarized with the exact language regulators objected to. Reading a handful of real letters is the fastest way to recalibrate your own copy. When you are ready, run your live pages through the Claim Checker one more time before you publish.

Frequently asked questions

Is it legal to market “generic” or “imported” Botox at a lower price?

No. The only injectable botulinum toxin products you can lawfully market and administer in the United States are the specific products the FDA has approved. Marketing a “generic,” “foreign,” or imported toxin as a cheaper alternative offers an unapproved new drug for sale, which is what drew the Beauty of Aztlan Warning Letter [3]. The safe path is to name only FDA-approved neurotoxins, describe them as prescription treatments performed after a consultation, and never list injectable toxin for direct online purchase.

Why would a unit-count discrepancy matter if my injections are fine?

Because the gap itself is the violation. When a med spa injects more units than it purchased, regulators read it as a sign that product is being sourced outside the legitimate supply chain or stretched through dilution, both of which raise misbranding and safety concerns. That reconciliation problem is what the FDA cited at Pure Indulgence Aesthetics [3]. Keeping purchase records that line up with administered volume, and buying only through authorized distributors, is the protection.

Can I keep saying a treatment has “no downtime” if that is usually true?

“Usually true” is the problem. “No downtime,” “risk-free,” and “permanent” are absolute claims, and absolute claims for neurotoxins and fillers are not substantiated, since results are temporary and every injectable carries some risk. That is the deceptive-advertising standard the FTC enforces [1][4]. Reframe to what you can support: “most clients return to normal activities the same day,” “results typically last three to four months,” and a plain note about common temporary side effects.

Does running the Claim Checker mean my copy is FDA-compliant?

No. The Claim Checker and this post are educational screening tools that flag language matching known enforcement patterns. They do not clear your marketing or your products, and they are not legal or regulatory advice. Your clinic’s own licensed physician and your counsel remain the final gate on every medical claim and every product you market.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5, deceptive or unfair acts). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.